Mesothelioma Clinical Trials Involve Gene Therapy
Treatment options for malignant mesothelioma may soon include customized gene therapy, according to thoracic surgeon and scientist Dr. Prasad Adusumilli at Memorial Sloan Kettering Cancer Center in New York. Gene therapy involves a laboratory reprogramming of a patient’s own T cells, which are a type of white blood cell, to recognize and destroy the cancer. The U.S. Food and Drug Administration (FDA) recently approved the first gene therapy specifically for pediatric leukemia, signaling the start of a new approach to cancer treatment in this country. The newly approved treatment is also known as chimeric antigen rece...
Source: Asbestos and Mesothelioma News - September 19, 2017 Category: Environmental Health Authors: Matt Mauney Tags: CAR T cell therapy checkpoint blockade chimeric antigen receptor T cell therapy Dr. Andy Haas Dr. Prasad Adusumilli Dr. Scott Gottlieb FDA Commissioner gene therapy cancer gene therapy for mesothelioma immunotherapy clinical trial mali Source Type: news
Trial Results Suggest Longer Mesothelioma Survival Possible with New...
Nintedanib boosted mesothelioma survival by more than five months in newly-published study.(PRWeb September 15, 2017)Read the full story at http://www.prweb.com/releases/2017/09/prweb14699696.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 15, 2017 Category: Pharmaceuticals Source Type: news
Rare genetic cause of peritoneal mesothelioma points to targeted therapy
(Brigham and Women's Hospital) BWH investigators have uncovered a new genetic cause of mesothelioma: a genetic rearrangement in the ALK gene, observed in three patients with peritoneal mesothelioma. Unlike previously known causes, this new discovery points to a potential therapeutic approach for those few patients whose tumors harbor the mutation. The team's findings are published in JAMA Oncology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 14, 2017 Category: Cancer & Oncology Source Type: news
Rare Genetic Cause of Peritoneal Mesothelioma Points to Targeted Therapy
Genetic rearrangement in the ALK gene found in young women with mesothelioma may be targetable with FDA-approved drugs. (Source: BWH for Journalists)
Source: BWH for Journalists - September 14, 2017 Category: Research Source Type: news
Rare Genetic Cause of Peritoneal Mesothelioma Points to Targeted Therapy
Genetic rearrangement in the ALK gene found in young women with mesothelioma may be targetable with FDA-approved drugs. (Source: BWH News)
Source: BWH News - September 14, 2017 Category: Hospital Management Source Type: news
Global Mesothelioma Deaths Remain High Despite Poor Data
An estimated 38,400 people around the world will die this year from mesothelioma cancer, according to a report recently published in Occupational & Environmental Medicine. The estimation by the international peer-reviewed journal included 230 countries. Data used for the study came from the World Health Organization’s (WHO) Mortality Database and extrapolated information based on gender- and age-specific death rates. “The global burden of mesothelioma is real,” Dr. Ken Takahashi, director of Asbestos Diseases Research Institute, University of Sydney Gate 3, Australia, told Asbestos.com. “It is v...
Source: Asbestos and Mesothelioma News - September 13, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Asbestos Diseases Research Institute asbestos-related lung cancer Australia mesothelioma Bangladesh Dr. Christina Fitzmaurice Dr. Ken Takahashi Global Burden of Disease Mesothelioma death rate mesothelioma latency period mesothelioma uni Source Type: news
Deadly Asbestos Still Widely Used Around the World
Asbestos is a toxic material that is known to cause mesothelioma, a form of cancer. The material is still used across the globe exposing people to the resulting mesothelioma.By Brook SpencerWALLINGFORD, CT, US, Sep 8 2017 (IPS)The worldwide impact cancer has is well known. It is the second leading cause of death globally, and according to the World Health Organization, was responsible for 8.8 million deaths in 2015. Globally, nearly 1 in 6 deaths are due to cancer and of those deaths approximately 70 percent occur in low and middle-income countries.Asbestos is a global problem that leads to real health risks – namely...
Source: IPS Inter Press Service - Health - September 8, 2017 Category: International Medicine & Public Health Authors: Brook Spencer Tags: Development & Aid Headlines Health Source Type: news
MD Anderson Retains Top Spot for Cancer Care
U.S. News & World Report ranked the MD Anderson Cancer Center in Houston the No. 1 cancer care hospital in America for the third consecutive year. MD Anderson has been a leader in the treatment of pleural mesothelioma, a contributing factor in maintaining its top billing on the rankings. Memorial Sloan Kettering in New York and Mayo Clinic in Rochester, Minnesota, were No. 2 and No. 3, respectively, in the 2017-18 Best Hospitals for Cancer listing. U.S. News & World Report — a global authority in hospital care — has published the rankings annually for 28 years, helping patients make tough health c...
Source: Asbestos and Mesothelioma News - September 6, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Barnes-Jewis Hospital best mesothelioma cancer centers Cardiology Cleveland Clinic Gastroenterology H. Lee Moffitt Cancer Center and Research Institute heart surgery Johns Hopkins Massachusetts General Hospital Mayo Clinic Mayo Clinic- Source Type: news
Mesothelioma Patients Survive Longer with Trimodal Treatment
Pleural mesothelioma patients who undergo aggressive multimodal treatment live almost twice as long after diagnosis than those who do not, according to a recent extensive study. Researchers at MD Anderson Cancer Center in Texas found a combination of surgery, chemotherapy and radiation extended survival time significantly, regardless of disease histology or cancer stage. “We recommend that all patients with [malignant pleural mesothelioma] be evaluated by multidisciplinary teams that are experienced in the management of mesothelioma for consideration of surgery-based, multimodality treatment,” the authors wrote...
Source: Asbestos and Mesothelioma News - September 5, 2017 Category: Environmental Health Authors: Matt Mauney Tags: biphasic histology Dr. Anne Tsao Dr. Boris Sepesi Dr. Daniel Gomez Dr. David Rice Dr. Mark Berry epithelial mesothelioma Journal of Clinical Oncology md anderson cancer center mesothelioma chemotherapy mesothelioma mortality surgery Source Type: news
Upcoming Mesothelioma Symposium Filled with Hope
Discussions About Immunotherapy for Mesothelioma Cameron also will speak about engineering mesenchymal stem cells for immunotherapy. Clare Cameron, who is the executive director of the Pacific Mesothelioma Center (PMC) and not related to Dr. Robert Cameron, will talk about resources for research. Lein Hua-Feng, a nurse practitioner at PMC, will discuss the benefits of caregiver support groups. “The symposium will provide an unrivaled opportunity for both the medically savvy and general public, including mesothelioma patients,” Clare Cameron said. “You’ll hear about the most promising medical advance...
Source: Asbestos and Mesothelioma News - August 29, 2017 Category: Environmental Health Authors: Matt Mauney Tags: 7th annual International Symposium on Mesothelioma Angiogenesis Inhibition and Chemotherapy Arti Shukia Banaras Hindu University bap1 Center at the University Hospital of Siena clare cameron Dr. Anna Nowak Dr. Brian Cunniff Dr. David Sch Source Type: news
Trump ’ s Halt on Coal Mining Study Has Asbestos Implications
The U.S. Department of the Interior has ordered a halt to a study on the public health risks of mountaintop removal mining in Appalachia — an area ripe with natural asbestos deposits. A letter from the Interior Department on Monday directed the National Academies of Sciences, Engineering and Medicine to “cease all work” on the study, citing responsible spending of taxpayer dollars as the reason for the decision. The $1 million National Academies study began in 2016 and was expected to take two years to complete. It aimed to evaluate health risks of a common mining technique for people living near surfac...
Source: Asbestos and Mesothelioma News - August 24, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Appalachian Mountains arsenic asbestos exposure Appalachia asbestos exposure coal mining asbestosis coal mining Bill Price Central Appalachia coal mining Appalachia Donald Trump Environmental Health Perspectives Glenda Owens House Co Source Type: news
Alternative Medicine Alone Leads to Lower Cancer Survival
Cancer patients who opt for alternative therapy instead of conventional medicine significantly decrease their chances of survival, according to researchers at Yale School of Medicine. Although the popularity of alternative medicine continues to grow, a recent study published in the Journal of the National Cancer Institute found survival rates significantly reduced for those who use it as first-line therapy. Conventional cancer treatments — chemotherapy, surgery and radiation — still produce a much better chance of survival. Mesothelioma was not included in the study, but the findings are relevant to this rare ...
Source: Asbestos and Mesothelioma News - August 23, 2017 Category: Environmental Health Authors: Matt Mauney Tags: acupuncture cancer Alternative medicine alternative mesothelioma treatment alternative therapy survival alternative vs conventional medicine breast cancer colon cancer Conventional cancer treatments Dr. David Gorski Dr. Skyler Johnson Source Type: news
Nearly One-Third of Mesothelioma Patients Remain Untreated
A new report from the National Cancer Institute (NCI) shows between 20 and 30 percent of malignant mesothelioma patients do not receive any cancer treatment. The study, “Patterns of care and survival among patients with malignant mesothelioma in the United States,” published August 10 in the journal Lung Cancer, aimed to describe the patterns of care and subsequent survival among mesothelioma patients in the U.S. while adjusting for patient demographics and pre-existing health conditions. Using the NCI’s Surveillance, Epidemiology, and End Results (SEER) data, researchers discovered significant differenc...
Source: Asbestos and Mesothelioma News - August 21, 2017 Category: Environmental Health Authors: Matt Mauney Tags: amount of mesothelioma patients eligible for surgery checkpoint inhibitors clinical trial enrollment cytoreduction surgery heated chemotherapy pleural mesothelioma heated intraperitoneal chemotherapy immunotherapy mesothelioma keytruda Lin Source Type: news
Mesothelioma, Asbestos Diseases Costly for Canadians
The annual cost of asbestos-related occupational disease in Canada is estimated at $2.35 billion, according to new findings by a panel of epidemiologists, public health experts and medical professionals. Their estimate is based on direct, indirect and quality-of-life costs related to the 2,331 patients in Canada diagnosed with mesothelioma or asbestos-related lung cancer in 2011. Occupational and Environmental Medicine, a monthly peer-reviewed medical journal, released the updated report in July. It followed a similar study conducted by the same group of experts in 2016. “When you look at the big picture [and] consid...
Source: Asbestos and Mesothelioma News - August 16, 2017 Category: Environmental Health Authors: Matt Mauney Tags: asbestos ban in canada asbestos mines canada asbestosis canada canada mesothelioma Dr. Emile Tompa economic burden asbestos canada financial burden mesothelioma canada health care costs mesothelioma canada House of Commons Occupational a Source Type: news
German Study Finds Novel Chemotherapy Technique Extends Mesothelioma...
Scientists say the key is confining chemotherapy drugs to the chest area, where they can have the most impact on the mesothelioma tumor.(PRWeb August 14, 2017)Read the full story at http://www.prweb.com/releases/2017/08/prweb14597411.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 14, 2017 Category: Pharmaceuticals Source Type: news
Lung-Sparing P/D Surgery Best for Mesothelioma Patients
The latest studies have shown, and most thoracic oncologists agree, that lung-sparing pleurectomy/decortication is a better surgical option for mesothelioma patients today than the more aggressive extrapleural pneumonectomy. Less is better. Quality of life becomes better, too. “In most instances, the pleurectomy/decortication is the operation of choice now,” thoracic surgeon Dr. Andrea Wolf at Mount Sinai Hospital in New York City, told Asbestos.com. “We’re finding that patients just do better in terms of survival and in terms of quality of life.” Wolf recently co-authored “The impact of...
Source: Asbestos and Mesothelioma News - August 9, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Annals of Translational Medicine best surgery for mesothelioma Dr. Andrea Wolf Dr. Hasan Batirel eligible for mesothelioma surgery extrapleural pneumonectomy lung-sparing surgery Marmara University Hospital mesothelioma histology mesothe Source Type: news
Promising Drug Reduces Growth of Aggressive Mesothelioma
Scientists in Italy have found a platinum-based drug that successfully lessens growth of the most aggressive type of mesothelioma cancer cells. Researchers at the University of Salento discovered the experimental drug Ptac2S was more effective in reducing the spread of sarcomatoid malignant pleural mesothelioma cells in mice compared to cisplatin — the most widely used chemotherapy drug for treating mesothelioma. Sarcomatoid is the least common of the three mesothelioma cell types but is considered more aggressive and harder to treat. A diagnosis with the sarcomatoid cell type is typically associated with a poor pro...
Source: Asbestos and Mesothelioma News - August 7, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Alimta alternatives to cisplatin Antonella Muscella Biphasic mesothelioma chemotherapy for mesothelioma chemotherapy resistance DNA adducts epithelioid mesothelioma genomic activities mesothelioma clinical trials mesothelioma survival Source Type: news
British Researchers Report Extended Mesothelioma Survival with New...
Scientists in Surrey and London say two peritoneal mesothelioma patients are still living 10 and 13 years after their diagnosis.(PRWeb August 03, 2017)Read the full story at http://www.prweb.com/releases/2017/08/prweb14567142.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 3, 2017 Category: Pharmaceuticals Source Type: news
Bayer ’ s Drug Failed to Improve Mesothelioma Survival
Drug manufacturers announced disappointing ends recently to two different clinical trials involving pleural mesothelioma, dampening earlier enthusiasm over the promise of immunotherapy. Anetumab ravtansine, manufactured by Bayer, and tremelimumab, from drugmaker AstraZeneca, failed an effectiveness test as a stand-alone, second-line treatment for mesothelioma, according to both manufacturers. “Malignant pleural mesothelioma is a very difficult-to-treat tumor, and we had hoped for a better outcome for patients,” said Robert LaCaze, an executive vice president at Bayer. Although trial officials have not released ...
Source: Asbestos and Mesothelioma News - July 27, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: anetumab ravtansine astrazeneca cancer drug bayer cancer drug bayer mesothelioma drug mesothelioma clinical trials tremelimumab Source Type: news
Researchers Announce They Are Stopping Trial of New Mesothelioma Drug,...
The makers of anetumab ravtansine say it failed to improve mesothelioma survival better than another drug.(PRWeb July 27, 2017)Read the full story at http://www.prweb.com/releases/2017/07/prweb14549214.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 27, 2017 Category: Pharmaceuticals Source Type: news
Pigment Found in Chamomile, Parsley Kills Mesothelioma Cells
A yellowish pigment common to parsley, celery, chamomile tea, oranges and grapefruit may be the latest treatment for mesothelioma cancer, a new study shows. While numerous studies have demonstrated the anti-cancer and antioxidant properties of apigenin (API), the natural pigment found in these plants and vegetables, researchers recently tested it against malignant mesothelioma cells. Doctors at the University of Rome evaluated the anti-tumor activities of API in mice injected with mesothelioma cells. API inhibited malignant mesothelioma (MM) cell survival and activated cell death, known as apoptosis. Mice treated with AP...
Source: Asbestos and Mesothelioma News - July 26, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: apigenin benefits apigenin for cancer apigenin for mesothelioma new mesothelioma treatment Source Type: news
Study Update Shows Tremelimumab Unlikely to Improve Mesothelioma...
Investigators now say the monoclonal antibody does not appear to work as a second- or third-line treatment option for mesothelioma patients.(PRWeb July 25, 2017)Read the full story at http://www.prweb.com/releases/2017/07/prweb14534100.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 25, 2017 Category: Pharmaceuticals Source Type: news
Bayer ’s Phase II trial for MPM drug fails to meet primary endpoint
Bayer ’s Phase II clinical trial of its oncology product candidate anetumab ravtansine (BAY 949343) did not meet the primary endpoint of progression-free survival in recurrent malignant pleural mesothelioma (MPM) patients. (Source: Drug Development Technology)
Source: Drug Development Technology - July 24, 2017 Category: Pharmaceuticals Source Type: news
Phase II Trial of Investigational Anetumab Ravtansine Does Not Meet Primary Endpoint in Second-Line Mesothelioma (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - July 21, 2017 Category: Pharmaceuticals Source Type: news
Bone Health Drug Inhibits Mesothelioma Tumor Growth
A drug used to treat bone disease and high blood calcium levels may carry benefits as part of a combination treatment for malignant pleural mesothelioma, a recent study concluded. Researchers at the University of Alabama at Birmingham Comprehensive Cancer Center conducted a pilot study testing the effects of zoledronic acid — a bisphosphonate, or bone health drug, marketed as Reclast and Zometa — against a small group of patients with unresectable pleural mesothelioma. The study, published in the June edition of Lung Cancer: Targets and Therapy journal, was a follow-up to preclinical research showing zoledron...
Source: Asbestos and Mesothelioma News - July 20, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: bone disease treatment keytruda mesothelioma treatments Muhammad Omer Jamil reclast treating malignant pleural mesothelioma University of Alabama at Birmingham Comprehensive Cancer Center Zoledronic acid zometa Source Type: news
Asbestos Found in Children ’ s Makeup
Justice, a national retail chain marketed to young girls, has stopped selling a cosmetics product after discovering it contained talc contaminated with asbestos fibers. The government-licensed Scientific Analytical Institute (SAI) in Greensboro, North Carolina, confirmed the asbestos contamination after testing the product as part of a Durham-based WTVD-TV news investigation. The tainted product was Just Shine Shimmer Powder, which the company stopped selling at stores and removed from its website, according to a Tuesday post on its Facebook page. “Our suppliers are required to produce all products in compliance wit...
Source: Asbestos and Mesothelioma News - July 19, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: asbestos contaminates makeup asbestos in children's makeup asbestos in makeup asbestos in products asbestos in talcum powder asbestos in toys makeup with asbestos Source Type: news
Pleural Mesothelioma Patients Needed for Trial of New Drug...
Preliminary tests of the VEGF-inhibitor nintedanib suggest that it can make mesothelioma chemotherapy more effective.(PRWeb July 17, 2017)Read the full story at http://www.prweb.com/releases/2017/07/prweb14512990.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 17, 2017 Category: Pharmaceuticals Source Type: news
Mesothelioma Clinical Trial Combines Immunotherapy Drugs
Dr. Tawee Tanvetyanon at the Moffitt Cancer Center in Tampa rarely sounds this enthused about the future prospects for patients with pleural mesothelioma. Finally, he has something promising to offer. Tanvetyanon is the principal investigator of a much-anticipated phase II clinical trial involving an immunotherapy drug combination with considerable potential for extending survival. “This is exciting. We now can offer something with realistic hope,” he told Asbestos.com. “We haven’t had anything like this for mesothelioma in a long time. I really look forward to speaking with these patients now.&rdqu...
Source: Asbestos and Mesothelioma News - July 13, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Abramson Cancer Center Aduro Biotech CRS-207 Dr. Tawee Tanvetyanon FDA approval Keytruda improving mesothelioma prognosis Merck mesothelioma chemotherapy mesothelioma clinical trials mesothelioma immunotherapy moffitt cancer center m Source Type: news
New Study Finds Hope for Mesothelioma Treatment in Measles Virus,...
Minnesota scientists say a particular strain of the measles virus is especially lethal to malignant mesothelioma cells and may form the basis of a new treatment.(PRWeb July 13, 2017)Read the full story at http://www.prweb.com/releases/2017/07/prweb14499292.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 13, 2017 Category: Pharmaceuticals Source Type: news
Asbestos Type Has No Effect on Mesothelioma Latency Period
New research from scientists in Germany sheds more light on the unusually long latency period associated with mesothelioma and other asbestos-related diseases. The study, published earlier this year in the European Respiratory Journal, is the first to track the presence of asbestos fibers in lung tissue over time. Mesothelioma has one of the longest latency periods of any cancer. It typically takes anywhere from 20 to 50 years after a person’s initial exposure to asbestos before symptoms arise. Using the German Mesothelioma Register, researchers at Ruhr-University Bochum discovered the volume of asbestos fibers in...
Source: Asbestos and Mesothelioma News - July 11, 2017 Category: Environmental Health Authors: Matt Mauney Tags: amosite amphibole asbestos exposure asbestos fiber burden asbestos fibers in lungs biopersistence of asbestos bronchoalveolar lavage Chrysotile asbestos Chrysotile asbestos fibers European Respiratory Journal German Mesothelioma Regist Source Type: news
Woman dies from cancer caused by hugging dad as a child
Susan Macgregor was diagnosed with mesothelioma in September 2015. Her family are devastated after the mother-of-three and fitness fanatic died just over a year later, aged 58. (Source: the Mail online | Health)
Source: the Mail online | Health - July 7, 2017 Category: Consumer Health News Source Type: news
SMART Protocol for Mesothelioma Adds Immunotherapy
In conclusion, we demonstrated the importance of the immune system in the benefit of clinical protocols using…radiation followed by surgery.” The post SMART Protocol for Mesothelioma Adds Immunotherapy appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - July 6, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: emerging treatments for mesothelioma immunotherapy for mesothelioma SMART mesothelioma SMART protocol mesothelioma smart protocol mix with immunotherapy Source Type: news
BAP1 Mesothelioma Mutation Focus of Upcoming Clinical Trial
Researchers at the University of Hawaii believe they are close to a fix for the genetic mutation that makes certain people more susceptible to developing mesothelioma cancer and more resistant to chemotherapy. Dr. Michele Carbone, director of thoracic oncology at the UH Cancer Center, said the BAP1 genetic mutation his research first uncovered in 2011 will be key to future prevention and treatment of mesothelioma. “I do not like to make promises,” Carbone told Asbestos.com. “But our record shows that we’ve always delivered more than we planned for. We have a pretty good idea how to fix it.” Hi...
Source: Asbestos and Mesothelioma News - July 5, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: bap1 gene mutation doctor michele carbone gene therapy for mesothelioma mesothelioma clinical trial university of hawaii cancer center Source Type: news
New Evidence Points to Benefits of Zoledronic Acid for Advanced...
The bisphosphonate may be an option for mesothelioma patients who are not benefitting from other treatments.(PRWeb July 01, 2017)Read the full story at http://www.prweb.com/releases/2017/07/prweb14478826.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 1, 2017 Category: Pharmaceuticals Source Type: news
New Mesothelioma Study Highlights Benefits of Compound in Cruciferous...
Korean researchers say sulforaphane may enhance the cancer-killing power of cisplatin.(PRWeb June 29, 2017)Read the full story at http://www.prweb.com/releases/2017/06/prweb14470048.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 29, 2017 Category: Pharmaceuticals Source Type: news
Seattle Cancer Center Opens Latest Mesothelioma Clinical Trial
The Seattle Cancer Care Alliance has opened a phase II clinical trial involving durvalumab, the promising immunotherapy drug, in combination with chemotherapy for the first-line treatment of unresectable pleural mesothelioma. The U.S. Food and Drug Administration (FDA) already granted accelerated approval to durvalumab in May for the treatment of bladder cancer. Researchers have also lauded the drug for its effectiveness in earlier lung cancer clinical trials. “We have every reason to believe it will be effective with mesothelioma, too,” Dr. Bernardo Goulart, chief trial investigator and medical oncologist at t...
Source: Asbestos and Mesothelioma News - June 27, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: cancer in seattle doctor Bernardo Goulart mesothelioma clinical trials mesothelioma in seattle mesothelioma treatment seattle cancer care alliance Source Type: news
Time Between Surgeries Helps Predict Mesothelioma Survival
A new study from researchers at the City of Hope cancer center in Los Angeles and Wake Forest University School of Medicine in Winston-Salem, North Carolina, reveals how the length of time between initial and follow-up cytoreduction surgery and HIPEC plays a role in patient survival. The study, published in June in the Journal of Surgical Oncology, shows peritoneal mesothelioma patients who repeat the procedure between one and two years after the initial surgery have the most favorable outcome, with a median overall survival of nearly four years. Peritoneal mesothelioma is an aggressive, asbestos-related cancer, and recu...
Source: Asbestos and Mesothelioma News - June 23, 2017 Category: Environmental Health Authors: Matt Mauney Tags: appendiceal cancer city of hope cancer center colon cancer cytoreduction surgery debulking surgery Dr. Konstantinos Votanopoulos gastrointestinal cancer heated intraperitoneal chemotherapy HIPEC Journal of Surgical Oncology moffitt can Source Type: news
Nintedanib Combination Delayed Progression in Malignant Mesothelioma
Adding nintedanib to pemetrexed/cisplatin improved the progression-free survival of patients with malignant pleural mesothelioma compared with placebo. (Source: CancerNetwork)
Source: CancerNetwork - June 22, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Lung Cancer News Source Type: news
Can a Breath Test Diagnose Mesothelioma in the Early Stages?
Much of mesothelioma research centers on identifying new and noninvasive biomarkers for earlier detection of the asbestos-related cancer. Progress has been made in finding biomarkers in blood and pleural effusions, but researchers in Belgium now believe the next breakthrough in early diagnosis for mesothelioma cancer may be a breath test. Researchers at Ghent University Hospital and Antwerp University Hospital recently highlighted the potential of breath analysis, called breathomics, as a noninvasive screening tool for malignant pleural mesothelioma. The Oncotarget medical journal published the study in May. Breath tests...
Source: Asbestos and Mesothelioma News - June 20, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Antwerp University Hospital biomarkers breath tests biomarkers for mesothelioma biopsies mesothelioma breath analysis mesothelioma breath test mesothelioma breathomics chromatography-mass spectrometry early detection of mesothelioma elec Source Type: news
New Trial Finds VEGF-Inhibitor May Safely Boost Mesothelioma...
Researchers say cediranib has “tolerable toxicity” and “promising efficacy” in the treatment of malignant mesothelioma.(PRWeb June 18, 2017)Read the full story at http://www.prweb.com/releases/2017/06/prweb14436904.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 18, 2017 Category: Pharmaceuticals Source Type: news
Mesothelioma Clinical Trial Opens with High Expectations
Newly diagnosed mesothelioma patients around the world have begun enrolling in a much-anticipated, phase III clinical trial involving an immunotherapy drug combination with groundbreaking potential. The trial, designed as first-line therapy for unresectable pleural mesothelioma, will measure the effectiveness of nivolumab (Opdivo) and ipilimumab (Yervoy) against standard-of-care chemotherapy. A presentation this month at the 2017 American Society of Clinical Oncology (ASCO) annual meeting sparked high expectations for the trial, detailing early, impressive effectiveness involving the two drugs in second-line and third-lin...
Source: Asbestos and Mesothelioma News - June 16, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Abramson Cancer Center American Society of Clinical Oncology Bristol-Myers Squibb cancer immunotherapy research cisplatin for mesothelioma Cleveland Clinic Cancer Center CRS-207 disease control rate Dr. Arnaud Scherpereel Dr. Patrick Ma Source Type: news
Research nurse receives grant for mesothelioma diagnosis work
A charity grant has been awarded to a nurse-led study that aims to reduce the need for diagnostic surgery via a new method involving light technology. (Source: Nursing Times)
Source: Nursing Times - June 13, 2017 Category: Nursing Source Type: news
How Math Is Reshaping Mesothelioma Chemotherapy
This study demonstrates the feasibility of this approach since both preliminary encouraging signs of activity and no unexpected toxicities were observed, in this heavily pre-treated patients’ population.” Study Size and Rarity of Mesothelioma Present Challenges As a phase I clinical trial, it is a novel approach at this point but a promising step for future chemotherapy treatment plan protocols. The limited number of patients in the study — nine NSCLC and three mesothelioma — is also problematic, but the planned second phase of the study will include the new model’s effect on the immune syste...
Source: Asbestos and Mesothelioma News - June 13, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Aix-Marseille University anemia chemotherapy best vinorelbine regimen chemotherapy side effects Fabrice Barlesi low-dose oral chemotherapy drugs math cancer chemotherapy math to fight cancer mathematical modeling cancer mesothelioma chem Source Type: news
Chemotherapy Mix Doubles Peritoneal Mesothelioma Survival
Surgeon Paul Sugarbaker at the Washington Cancer Institute has nearly doubled the five-year survival rate for patients with peritoneal mesothelioma by adding long-term regional chemotherapy to his already groundbreaking protocol. Sugarbaker, a pioneer in advancing peritoneal mesothelioma treatment for more than two decades, believes this latest development could have far-reaching implications. “This could be a game changer,” Sugarbaker told Asbestos.com. “The reaction has been, ‘Wow! [It’s] hard to believe.’ We’ve got to exploit this [advancement] as best as we can.” Sugarbak...
Source: Asbestos and Mesothelioma News - June 7, 2017 Category: Environmental Health Authors: Matt Mauney Tags: cytoreductive surgery epithelioid cell type European Journal of Surgical Oncology HIPEC hyperthermic perioperative chemotherapy International Journal of Hyperthermia intraperitoneal chemotherapy long-term regional chemotherapy MedStar Wash Source Type: news
Immunotherapy Yields ‘Dramatic’ Response Rates in Relapsed Mesothelioma
Immunotherapy may represent an effective new treatment approach for relapsed mesothelioma patients, according to a new study. (Source: CancerNetwork)
Source: CancerNetwork - June 7, 2017 Category: Cancer & Oncology Authors: Mark L. Fuerst Tags: Conferences/ASCO Lung Cancer News Source Type: news
Using Viruses to Boost Mesothelioma Immunotherapy
Immunotherapy through clinical trials is becoming a promising treatment option for some mesothelioma patients. Checkpoint inhibitor drugs, such as Keytruda, already have U.S. Food and Drug Administration (FDA) approval as first-line treatments for non-small cell lung cancer (NSCLC), edging immunotherapy drugs closer to becoming a viable second-line therapy for other thoracic cancers, including pleural mesothelioma. However, overall response to immune therapies remains relatively low. Researchers across the country are striving to enhance responsiveness to immunotherapy drugs. Leading that trend is viroimmunotherapy, or t...
Source: Asbestos and Mesothelioma News - June 6, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Biomedicines checkpoint blockade Checkpoint inhibitor drugs clinical trials for mesothelioma Dr. Alexander Dash Dr. Manish Patel FDA approval Keytruda immune response cancer immunotherapy response mesothelioma intratumoral injections k Source Type: news
Immunotherapy Shows Promise in Tough-to-Treat Mesothelioma
(MedPage Today) -- Outcomes improved with nivolumab alone or with impilimumab in pretreated patients (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - June 5, 2017 Category: General Medicine Source Type: news
Likely New Option for Mesothelioma: Immunotherapy Likely New Option for Mesothelioma: Immunotherapy
With new data available, experts predicted that checkpoint inhibitors will be added to the sparse treatment options for this deadly lung cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 5, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Early research suggests first immunotherapy for mesothelioma on the horizon
(American Society of Clinical Oncology) Malignant pleural mesothelioma or MPM is a rare cancer, but its incidence has been rising. This cancer is usually associated with asbestos exposure, and patients have a median life expectancy of only 13-15 months. All patients relapse despite initial chemotherapy, more than 50% of them within six months after stopping treatment. There are currently no effective therapeutic options for patients with MPM. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 5, 2017 Category: Cancer & Oncology Source Type: news
New Mesothelioma Study Finds Cholesterol Drug Could Guard Against...
Japanese researchers say a statin drug may help make radiotherapy more effective for people with malignant mesothelioma.(PRWeb June 04, 2017)Read the full story at http://www.prweb.com/releases/2017/06/prweb14394603.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 4, 2017 Category: Pharmaceuticals Source Type: news